长春高新：收到GenSci098注射液项目7000万美元首笔付款

Core Viewpoint - Changchun High-tech (000661) has made progress in the GenSci098 injection project by signing an exclusive licensing agreement, receiving an initial payment of $70 million from Yarrow [1] Group 1: Company Developments - The company's subsidiary, Jinsai Pharmaceutical, through its wholly-owned subsidiary, Saizeng Medical, has entered into an exclusive licensing agreement with Yarrow for the GenSci098 injection project [1] - GenSci098 injection is a humanized TSH receptor antagonist monoclonal antibody developed by Jinsai Pharmaceutical, classified as a first-class new drug for therapeutic biological products [1]